Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

Donya Moradi Manesh, Jad El-Hoss, Kathryn Evans, Jennifer Richmond, Cara E. Toscan, Lauryn S. Bracken, Ashlee Hedrick, Rosemary Sutton, Glenn M. Marshall, William R. Wilson, Raushan T. Kurmasheva, Catherine Billups, Peter J. Houghton, Malcolm A. Smith, Hernan Carol, Richard B. Lock

Blood (2015) 126 (10): 1193–1202.

https://doi.org/10.1182/blood-2014-12-618900

Published: 2015

Includes: Supplemental data

Journal Articles

Array-Based Genomic and Transcriptomic Profiling in Pediatric Acute Leukemias in Search of Genes Responsible for Cyclophosphamide Resistance

Joanna Szczepanek, Joanna Laskowska, Joanna Lewandowska-Bieniek, Andrzej Tretyn, Jan Styczynski, MD PhD

Blood (2014) 124 (21): 3802.

https://doi.org/10.1182/blood.V124.21.3802.3802

Published: 2014

Journal Articles

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Juliana M Benito, PhD, Hongbo Lu, William R Wilson, PhD, Teresa J Melink, NP, MSN, Jennie Bretz, Sergej Konoplev, MD, PhD, Elihu H. Estey, MD, Hagop M. Kantarjian, MD, John C Gutheil, MD, Michael Andreeff, MD, PhD, Marina Konopleva, M.D., Ph.D.

Blood (2012) 120 (21): 3615.

https://doi.org/10.1182/blood.V120.21.3615.3615

Published: 2012

Journal Articles

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Marina Konopleva, M.D., Ph.D., Gautam Borthakur, Peter F Thall, PhD, Andrew Coveler, MD, Farhad Ravandi, MD, Elias Jabbour, Hoang Q Nguyen, PhD, Juliana M Benito, PhD, Yongchuan Gu, PhD, William R Wilson, PhD, Teresa J Melink, NP, MSN, Hagop M. Kantarjian, John C Gutheil, MD, Elihu H Estey, MD

Blood (2011) 118 (21): 1523.

https://doi.org/10.1182/blood.V118.21.1523.1523

Published: 2011

Journal Articles

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Heather L. Tardif, Song Yao, PhD, Bryan H. Goldman, MS, Catherine M. Spier, MD, Michael L. LeBlanc, PhD, Lisa M. Rimsza, MD, Daniel O. Persky, MD, Thomas P. Miller, MD, Richard I Fisher, MD, Christine B. Ambrosone, PhD, Margaret M. Briehl, PhD

Blood (2010) 116 (21): 321.

https://doi.org/10.1182/blood.V116.21.321.321

Published: 2010

NARROW

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

Array-Based Genomic and Transcriptomic Profiling in Pediatric Acute Leukemias in Search of Genes Responsible for Cyclophosphamide Resistance

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Email alerts

ASH Publications

American Society of Hematology

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

Array-Based Genomic and Transcriptomic Profiling in Pediatric Acute Leukemias in Search of Genes Responsible for Cyclophosphamide Resistance

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only